Navellier & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,840
| Closed | -$220K | – | 374 |
|
|
2026
Q1 | $220K | Buy |
+7,840
| New | +$209K | 0.02% | 311 |
|
|
2025
Q1 | – | Sell |
-7,840
| Closed | -$208K | – | 364 |
|
|
2024
Q4 | $208K | Sell |
7,840
-6,778
| -46% | -$184K | 0.02% | 313 |
|
|
2024
Q3 | $423K | Hold |
14,618
| – | – | 0.06% | 240 |
|
|
2024
Q2 | $409K | Hold |
14,618
| – | – | 0.05% | 267 |
|
|
2024
Q1 | $406K | Hold |
14,618
| – | – | 0.05% | 265 |
|
|
2023
Q4 | $421K | Sell |
14,618
-5,872
| -29% | -$178K | 0.06% | 241 |
|
|
2023
Q3 | $680K | Buy |
+20,490
| New | +$725K | 0.12% | 175 |
|
|
2021
Q1 | – | Sell |
-59,162
| Closed | -$2.18M | – | 311 |
|
|
2020
Q4 | $2.18M | Sell |
59,162
-6,770
| -10% | -$248K | 0.39% | 84 |
|
|
2020
Q3 | $2.3M | Sell |
65,932
-5,468
| -8% | -$192K | 0.5% | 71 |
|
|
2020
Q2 | $2.21M | Sell |
71,400
-4,215
| -6% | -$143K | 0.53% | 65 |
|
|
2020
Q1 | $2.34M | Sell |
75,615
-6,472
| -8% | -$221K | 0.55% | 45 |
|
|
2019
Q4 | $3.05M | Buy |
82,087
+1,542
| +2% | +$54.9K | 0.49% | 57 |
|
|
2019
Q3 | $2.75M | Buy |
80,545
+5,658
| +8% | +$206K | 0.45% | 59 |
|
|
2019
Q2 | $3.08M | Buy |
74,887
+2,019
| +3% | +$80.2K | 0.48% | 55 |
|
|
2019
Q1 | $2.94M | Sell |
72,868
-248
| -0.3% | -$9.93K | 0.46% | 61 |
|
|
2018
Q4 | $3.03M | Buy |
73,116
+513
| +0.7% | +$21.3K | 0.51% | 41 |
|
|
2018
Q3 | $3.04M | Sell |
72,603
-223
| -0.3% | -$8.59K | 0.39% | 74 |
|
|
2018
Q2 | $2.51M | Buy |
72,826
+1,095
| +2% | +$37.4K | 0.35% | 87 |
|
|
2018
Q1 | $2.42M | Buy |
71,731
+60,905
| +563% | +$2.09M | 0.37% | 81 |
|
|
2017
Q4 | $372K | Buy |
10,826
+447
| +4% | +$15.2K | 0.07% | 209 |
|
|
2017
Q3 | $352K | Sell |
10,379
-414
| -4% | -$13.3K | 0.07% | 178 |
|
|
2017
Q2 | $344K | Sell |
10,793
-280
| -3% | -$8.83K | 0.05% | 233 |
|
|
2017
Q1 | $359K | Buy |
11,073
+749
| +7% | +$23.6K | 0.05% | 225 |
|
|
2016
Q4 | $318K | Sell |
10,324
-644
| -6% | -$19.7K | 0.05% | 218 |
|
|
2016
Q3 | $352K | Buy |
10,968
+4,225
| +63% | +$141K | 0.05% | 190 |
|
|
2016
Q2 | $225K | Buy |
+6,743
| New | +$215K | 0.03% | 217 |
|
|
2014
Q1 | – | Sell |
-7,322
| Closed | -$213K | – | 342 |
|
|
2013
Q4 | $213K | Buy |
+7,322
| New | +$213K | 0.01% | 298 |
|
Other funds holding PFE
Navellier & Associates's PFE Position: Q2 2026 in Review
Navellier & Associates sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,840 shares — an estimated $220K sold.
Navellier & Associates first reported a position in PFE in Q4 2013 and held it in 27 quarters. The position peaked at $3.08M in Q2 2019. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Navellier & Associates reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Navellier & Associates sold 7,840 Pfizer shares in Q2 2026, an estimated $220K.
- Navellier & Associates first reported a position in Pfizer in Q4 2013 and held it in 27 quarters.
- Navellier & Associates's Pfizer position peaked at $3.08M in Q2 2019.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.